TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07472491: A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

Sponsor: GE Healthcare · Phase: PHASE2/PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 640 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$15,147,520

Rescue Site Savings

+$9,987,896

Unlock Full NCT07472491 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07472491 Rescue Dossier →